Related Experiment Videos
[Thrombocyte functions in malignant blood diseases]
Vutreshni Bolesti
|January 1, 1987
Summary
Platelet aggregation and secretion are often disturbed in leukemia and myeloma patients. However, these in vitro platelet function changes do not correlate with bleeding or clotting risks.
Area of Science:
- Hematology
- Oncology
- Hemostasis
Context:
- Malignant blood diseases, including chronic lymphoid leukemia, myeloma, chronic myeloid leukemia, and acute leukemia, can affect various bodily functions.
- Platelet function is crucial for hemostasis, and its alterations may occur in these conditions.
Purpose:
- To investigate platelet aggregation and secretion in patients with different types of leukemia and myeloma.
- To determine the relationship between in vitro platelet function tests and clinical hemostatic complications.
Summary:
- Platelet aggregation induced by various agents and platelet secretion were analyzed in patients with chronic lymphoid leukemia, myeloma, chronic myeloid leukemia, and acute leukemia.
- Disturbed platelet aggregation, particularly with adrenaline, and impaired secretion were frequently observed in these hematologic malignancies.
- Notably, no correlation was found between the observed in vitro platelet functional disturbances and the clinical presentation of hemostatic abnormalities, such as hemorrhages or thrombosis.
Impact:
- This study highlights that altered platelet function in vitro may not accurately predict bleeding or clotting risks in patients with hematologic malignancies.
- Understanding these discrepancies is vital for managing hemostasis in cancer patients and may guide future research into more predictive biomarkers.